Vascular Biology in Clinical Practice © Vol. 6, No. 3
• A HOPE FOR PEACE?
Update on the role of ACE inhibition
in CAD patients
This monograph, A HOPE for PEACE? Update on the role of ACE inhibition in CAD patients
, is offered as part of a series of continuing medical education activities from the University of Florida College of Medicine. Co-editors are Carl J. Pepine, MD, University of Florida College of Medicine, and Jeffrey L. Probstfield, MD, University of Washington, Seattle.
New guidelines jointly issued in 2004 by the American College of Cardiology and the American Heart Association expand their recommendations for angiotensin-converting enzyme inhibitors (ACEIs) in postdischarge care of patients following myocardial infarction. The new ACC/AHA recommendations were based on the results of two previous trials--the Heart Outcomes Prevention Evaluation (HOPE) and the EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease (EUROPA). A third major trial in patients with coronary artery disease--Prevention of Events with Angiotensin Converting Enzyme inhibition (PEACE)--was recently reported. PEACE did not show a significant effect on primary or secondary outcomes, although the confidence intervals overlapped with those of HOPE and EUROPA. PEACE and its implications on the role of ACEIs in preventing cardiovascular events are reviewed in this monograph.
The contents of this monograph express the views of the
individual contributors and do not necessarily reflect the views or
recommendations of the University of Florida College of Medicine,
University of Washington Seattle, or the publisher. The reader is
advised to consult the full prescribing information for all medications
prior to use.
Supported by an educational grant from Wyeth Pharmaceuticals and
King Pharmaceuticals Inc.
© 2004 Medical Education Consultants, LLCSM (MEDCON).
All rights reserved.